{"section": [{"title": "Remarks by Travis Steed", "id": 1, "section": [{"id": 2, "text": "Good morning everybody. Thanks for taking the question. I guess, Jay, just to start out, bridging the gap and the changes in the 2022 guidance but -- would be helpful. But more importantly, we'd love to see if you would provide some initial thoughts on 2023, if you'd commit to some of earnings growth off the 360 for next year and still at 75 basis points of margin expansion as before?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Travis Steed\", \"section_number\": 1, \"uuid\": \"d31f2038-148d-4ce4-ac68-9cad4a0eaf2b\", \"speaker_title\": \"Analyst at Bank of America Securities\"}"}]}, {"title": "Remarks by James Saccaro", "id": 3, "section": [{"id": 4, "text": "Sure. Travis, I missed the first part of the question.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 2, \"uuid\": \"115c3dc8-e50c-4880-8631-934dcce687f5\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Clare Trachtman", "id": 5, "section": [{"id": 6, "text": "2022 bridge for the EPS guidance.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Clare Trachtman\", \"section_number\": 3, \"uuid\": \"487566ab-1de0-49ce-9e08-d234fea8eadf\", \"speaker_title\": \"Vice President of Investor Relations at Baxter International\"}"}]}, {"title": "Remarks by James Saccaro", "id": 7, "section": [{"id": 8, "text": "Okay. Great. So yes, let's walk through the different pieces. I think all of these are starting to set up well for 2023, but it starts with the third quarter. Overall, Q3 came in largely in line with our expectations. We were pleased to put $0.82 in the books. And really, the commercial operations were off $0.02, in large part related to shortfalls in sales driven by supply constraints in certain areas. The tax rate and FX came in a little bit worse than our expectations. But offsetting this, and I think this is important to note, was better-than-anticipated performance in our supply chain.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 4, \"uuid\": \"9ae1b3b1-e083-437d-983f-0e7fcecbb706\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}, {"id": 9, "text": "As you know, this has been an area of extreme volatility for us as we've navigated the complicated macro environment. So it was really nice to see our supply chain team deliver in the quarter and set the stage for the fourth quarter and beyond. Now as we go to Q4, with respect to EPS, we now expect roughly a $0.05 headwind from foreign exchange, tax and interest relative to our previously issued guidance. On a year-over-year basis, these items impact us roughly $0.15.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"James Saccaro\", \"section_number\": 4, \"uuid\": \"9ae1b3b1-e083-437d-983f-0e7fcecbb706\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}, {"id": 10, "text": "And so we expect a continued supply constrained environment on the sales line. This is an area that we're navigating very carefully. But overall, the real driver in the fourth quarter relates to this headwind from these nonoperational items. So now as we transition to next year, what I've previously shared with you all is a template which says 4% to 5% compounded sales growth, minimum 75 basis points of operating margin expansion in a given year. As we thought about 2023, the sales growth will come in on the lower end of the range, closer to 4%, in large part because of lower levels of COVID vaccines emanating from our BPS business.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"James Saccaro\", \"section_number\": 4, \"uuid\": \"9ae1b3b1-e083-437d-983f-0e7fcecbb706\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}, {"id": 11, "text": "But as it relates to margin, through continued focus on costs, through execution of our Hillrom synergies, along with a real and significant impact of value improvement programs in our plans, what we can confirm at this point the 75 basis points of margin expansion. Now of course, we're going through our plan as we speak. And I will tell you that the world has been extremely volatile, but it was -- it's very nice to be able to share that with you at this point in time. And a lot of this comes down to stability coming out of our supply chain organization. Now the one thing I will say is, part of the reason we're not seeing accelerated sales growth is, as we look at 2023, there are continued headwinds from a supply constraint standpoint.", "metadata_json": "{\"paragraph_number\": 4, \"speaker\": \"James Saccaro\", \"section_number\": 4, \"uuid\": \"9ae1b3b1-e083-437d-983f-0e7fcecbb706\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}, {"id": 12, "text": "So we're going to expect to see component challenges through parts of 2023 in other areas. And so that's from a supply -- and semiconductors will continue to be challenging as we move through next year. So that's going to be something that we have to live with for a while. We're hoping that rehabilitates over the course of next year and certainly provides a tailwind as we move to 2024. Now moving to some other items. As we look at foreign exchange, that's going to be fairly neutral to operating margin, but it will be a roughly $0.15 headwind year-over-year, and a lot of that will be concentrated in the first half of the year because we've seen rates really deteriorate in Q3 and Q4.", "metadata_json": "{\"paragraph_number\": 5, \"speaker\": \"James Saccaro\", \"section_number\": 4, \"uuid\": \"9ae1b3b1-e083-437d-983f-0e7fcecbb706\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}, {"id": 13, "text": "And then from an interest expense standpoint, we're looking at approximately a $0.15 headwind. So this is a -- before that, and the interest rate will start to become a tailwind later on in this long-range plan. And so I think for us, as we sit here today, we feel really good about the prospects going into 2023. And so we've been dealing with a lot of volatility and I think really putting controls in place to navigate some of that, I mean I think, our ability to confirm that 2023 is an important step as we move forward. Joe, I don't know if you'd want to add anything to that.", "metadata_json": "{\"paragraph_number\": 6, \"speaker\": \"James Saccaro\", \"section_number\": 4, \"uuid\": \"9ae1b3b1-e083-437d-983f-0e7fcecbb706\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 14, "section": [{"id": 15, "text": "No. You covered it all. Thanks Jay.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 5, \"uuid\": \"a2df670b-68cf-4647-9c47-26babe764f36\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by Travis Steed", "id": 16, "section": [{"id": 17, "text": "Thanks. A quick follow-up, just to make sure. I think putting that all together, it still sounds like earnings can be up next year versus 2022. And on the 75 basis points, what does that assume on the $1 billion inflation? Does it assume that's stable? And does it assume no Novum IQ?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Travis Steed\", \"section_number\": 6, \"uuid\": \"fc1f539b-4862-4e2a-8ce6-dfbee0f5fa8a\", \"speaker_title\": \"Analyst at Bank of America Securities\"}"}]}, {"title": "Remarks by James Saccaro", "id": 18, "section": [{"id": 19, "text": "Okay. So as it relates to EPS, I think there's a little bit of EPS growth as we look at it based on some of the nonoperational items impacting us, but we do expect some level as we look at it. And then I'm sorry, I missed the second part of your question, I couldn't quite hear that.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 7, \"uuid\": \"f3f29c04-4d51-4a82-b0f0-13bfc336ae9b\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Travis Steed", "id": 20, "section": [{"id": 21, "text": "Well, the 75 basis points, what's assumed and or not on inflation in Novum IQ?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Travis Steed\", \"section_number\": 8, \"uuid\": \"7a197091-b9e7-4c85-8398-b3b848f43cd7\", \"speaker_title\": \"Analyst at Bank of America Securities\"}"}]}, {"title": "Remarks by James Saccaro", "id": 22, "section": [{"id": 23, "text": "Okay. So from an inflationary standpoint, I think we're looking at kind of consistent levels to today. So we're not anticipating significant price up in any commodities. We're anticipating some slight improvement in certain areas but also some negatives related to utilities, for example, in Europe. Joe, you want to address the Novum question?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 9, \"uuid\": \"97f97499-0d71-456d-9549-f22ce4ec5b0a\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 24, "section": [{"id": 25, "text": "I will. So we always preface any conversation on products which are not approved that we do not speak on behalf of the FDA. We believe that we have successfully resolved the issue that was the primary subject of the FDA's last additional information request. We referenced this issue on the Q2 call. We will submit data that we believe demonstrates successful resolution of the insurance part of our response. Since that time, we have identified additional software changes we're planning to implement proactively in consultation with the FDA.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 10, \"uuid\": \"ff25076d-e50f-4812-9023-29a58d6b7ca7\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 26, "text": "We're in the process of updating our response. And because of that, we're doing everything we can to submit our response as quickly as possible while we hope that to be in a position to submit those responses by late Q4, it may spill over into a couple of weeks of January, maybe half January. So we're doing the best we can to pull this together. We are very comprehensive in how we answer the FDA. We work very collaboratively with them, and we want to make sure that the product has all the information before we send to them. So there's no further request for information. That's our objective.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Jose E. Almeida\", \"section_number\": 10, \"uuid\": \"ff25076d-e50f-4812-9023-29a58d6b7ca7\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by Travis Steed", "id": 27, "section": [{"id": 28, "text": "That is really helpful color. Thanks a lot for taking the question.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Travis Steed\", \"section_number\": 11, \"uuid\": \"a7f93757-6f6a-4a46-8124-ffb4adf554b5\", \"speaker_title\": \"Analyst at Bank of America Securities\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 29, "section": [{"id": 30, "text": "Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 12, \"uuid\": \"90a8c187-08c4-4e15-855c-030f92ca4413\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by Robbie Marcus", "id": 31, "section": [{"id": 32, "text": "Great. Thanks. Maybe I could start off on capital allocation, how you're thinking about the business mix. We saw some reports in the news about potential sales or divestitures of some of the assets within renal that were low to no growth and low to negative margin. Maybe just give us a sense of how you're thinking about your portfolio here in the environment to get deals done, whether it's additive or a subtraction.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Robbie Marcus\", \"section_number\": 14, \"uuid\": \"e3f23ab3-ce6d-4594-b95b-d6fd19229724\", \"speaker_title\": \"Analyst at JPMorgan\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 33, "section": [{"id": 34, "text": "Robbie, good morning. We are actively looking -- first of all, I'm not going to comment on the rumors from the market, but I'm going to tell you what we are doing. We are actively looking at portfolio of the company. We will be ready to speak about that by early January, not at the moment. But I can tell you some bits of information what is going on. We are looking at every opportunity in the company to focus on the vision that we have set forth during our Investor Day back in May, which is connected care, the areas that will drive higher gross margin, areas of higher top line growth, software and the ability to be ahead of connecting the dots for clinicians and institutions.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 15, \"uuid\": \"62e8b36e-36a4-4461-969c-609fc6b7f140\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 35, "text": "So when we look at that, we look at our portfolio. Some products will make sense for us to retain. Some products will not. So we are looking to optimize our portfolio. We are about 3/4 of, of the way there in terms of understanding. And we will make a decision with our Board of Directors and then come forward with what we think is going to be the new portfolio of Baxter going forward, as I said early January. So I want to just also underscore that any portfolio movement which implies sale of assets or any kind of transaction, always, always takes into account, number one, creation of shareholder value. It's never secondary. Never secondary. It's always primary and that is creation of improved return on invested capital with accretion of value through discount cash flows. So we're going through this process. It's been very, very intense.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Jose E. Almeida\", \"section_number\": 15, \"uuid\": \"62e8b36e-36a4-4461-969c-609fc6b7f140\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 36, "text": "And we hope to have the new set of businesses going forward and what we're going to deal within and how we're going to suffice our mission and vision by, as I said, early January.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Jose E. Almeida\", \"section_number\": 15, \"uuid\": \"62e8b36e-36a4-4461-969c-609fc6b7f140\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by Robbie Marcus", "id": 37, "section": [{"id": 38, "text": "Great. Maybe just as a follow-up, Jay, you talked about something like $100 million in, I guess, theoretical lost sales in the quarter from supply chain issues but also about how the supply chain was a positive in the quarter and helped the margins. How should we think about those two reconciling next year? And in that 4% growth and the 75 bps of margin, how should we think about what's being resolved in the backlog? And how much improvement we'll be seeing in the supply chain? Thanks a lot.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Robbie Marcus\", \"section_number\": 16, \"uuid\": \"5b01f309-96d4-4a8a-a3e5-ec673b9ee284\", \"speaker_title\": \"Analyst at JPMorgan\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 39, "section": [{"id": 40, "text": "Robbie, I'll let Jay really comment on the numbers. So I will tell you about a couple of aspects. What we are seeing, supply chain is performing well against a very set -- difficult sets of circumstances as we said, labor inflation and material inflation have been significant to Baxter, and they're doing a great job navigating through that. Our procurement group is doing a heroic job getting the products to us. What is happening is there is a significant amount of backlog and back order for the company on products depending on semiconductors.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 17, \"uuid\": \"7046aa74-5547-4263-ab39-68b53ed72a39\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 41, "text": "And it's not one company or two. It's several. It's a plethora of companies that produce products for us, and we source semiconductors from them. What, a couple of things that we are doing that I feel more confident that throughout 2023, the situation will be more -- will be better, is that we are developing long-term relationships directly with the manufacturers of the chips instead of going to distributors or going directly to board assemblers.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Jose E. Almeida\", \"section_number\": 17, \"uuid\": \"7046aa74-5547-4263-ab39-68b53ed72a39\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 42, "text": "The second thing is, the amount of decommit the companies are coming forward during the quarter makes sometimes very difficult for us to predict what we can assemble and ship at the end of the quarter. It's getting better into 2023 as our supply chain now has a full view of commitments into 2023 what we need to make our growth. Business that had been very affected by this are Front Line Care, which is our business under our acquisition of Hillrom; our PSS, Patient Support Systems, the ability to make more pumps. We have very good demand for our current pump, our SIGMA SPECTRUM pump.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Jose E. Almeida\", \"section_number\": 17, \"uuid\": \"7046aa74-5547-4263-ab39-68b53ed72a39\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 43, "text": "We can make more because we're missing two or three key components that are in shortage in the marketplace due to high demand from other sources in the automotive and other areas. So what I can tell you is we are doing everything we can and the supply -- the supply constraint is really what has impacted Baxter's performance on the top line. Now VIPs, our value improvement programs, have been a significant driver of cost reduction for us in our operations. I'll pass on to Jay to give you more clarity on numbers that you asked.", "metadata_json": "{\"paragraph_number\": 4, \"speaker\": \"Jose E. Almeida\", \"section_number\": 17, \"uuid\": \"7046aa74-5547-4263-ab39-68b53ed72a39\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by James Saccaro", "id": 44, "section": [{"id": 45, "text": "Sure. Robbie, as we move to next year, we continue to assume a constrained top line due to semiconductors and availability of other components. So that does not fully resolve next year. We do expect to see some improvement and no deterioration relative to today's level, but we will live with this throughout most of next year. As we think about the margin improvement really, that's emanating from a significant improvement in value improvement programs, things like automation initiatives that we have going on in the plant, and that really helps support the 75-basis points improvement that we've discussed.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 18, \"uuid\": \"e66d2ad4-264b-4178-a26d-835ea738d350\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}, {"id": 46, "text": "We'll see lower-than-expected freight, and we're only targeting roughly 75 basis points or in excess of 75 basis points because we don't have a big commodity easing assumption in the numbers that we're sharing. To the extent that materializes, certainly, that could be an upside, but we're not banking on that at this point. We're banking on living in a challenging commodity world for 2023, for the most part, along with a supply-constrained world. Those two items are very big uncertainties. I'm hopeful that we take a conservative position and those break way over the course of the year, but we'll have to watch that very carefully.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"James Saccaro\", \"section_number\": 18, \"uuid\": \"e66d2ad4-264b-4178-a26d-835ea738d350\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Robbie Marcus", "id": 47, "section": [{"id": 48, "text": "Great. Thanks a lot.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Robbie Marcus\", \"section_number\": 19, \"uuid\": \"9a7b0892-6333-4897-bafa-0009d65b0681\", \"speaker_title\": \"Analyst at JPMorgan\"}"}]}, {"title": "Remarks by James Saccaro", "id": 49, "section": [{"id": 50, "text": "Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 20, \"uuid\": \"cbcfcaa2-f51d-44c8-85e2-e1d759bef730\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Rick Wise", "id": 51, "section": [{"id": 52, "text": "Good morning, Joe. Hi, Jay. I thought I'd focus on Hillrom, which you described as down mid-single digits. First, I wanted to understand -- is the decline -- if I think of Hillrom maybe as a mid-single-digit-ish kind of grower, was the decline -- to what degree was it integration bumps with Baxter? To what extent was it components? Was it all supplying components? Just -- I'd just like to frame that. And Joe, when do you think -- based on what you know today, Hillrom could return to being Hillrom for you? Is it going to take into '24? Do you think it's second half of next year? And then I have a follow-up question also related to Hillrom.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Rick Wise\", \"section_number\": 22, \"uuid\": \"f183a483-5338-438e-98b1-f8482e97d1df\", \"speaker_title\": \"Analyst at Stifel\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 53, "section": [{"id": 54, "text": "Rick, I'm going to have Jay answer that. I'll close answering the question, but Jay should start.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 23, \"uuid\": \"b3f559af-9ff5-474e-80b4-c17be6275af0\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by James Saccaro", "id": 55, "section": [{"id": 56, "text": "Yes, sure. Overall, Rick, Hillrom did decline in the quarter roughly 5% and is down roughly 1% year-to-date. And what's interesting is that demand for Hillrom products remains incredibly strong. We've seen historic levels of backlog in our Front Line Care business. We've seen backlog in our PSS business as well. So as we look at the portfolio of products, the innovation, the complementarity with the Baxter portfolio, we're incredibly excited. And the environment for their orders has been fairly strong throughout the year. It's been fairly consistent.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 24, \"uuid\": \"e5345f43-e692-402c-a4ae-0bcca407eaa0\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}, {"id": 57, "text": "But we've had severe supply constraints. And so without supply constraints, Hillrom would have been probably flat in the third quarter and, on a year-to-date basis, would be growing close to mid-single digits, which I would characterize as kind of where we would have hoped it would have been. But with these supply constraints that have been extremely challenging, in particular, in the case of Front Line Care, it's been hard to get to the sales level that we hoped for. So Joe, maybe you might want to add to that.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"James Saccaro\", \"section_number\": 24, \"uuid\": \"e5345f43-e692-402c-a4ae-0bcca407eaa0\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 58, "section": [{"id": 59, "text": "Yes. Rick, we have done, as a company, a very thorough integration job here. Our synergies are coming higher, much higher than we had estimated in the first year of the integration. Our supply chain people had to come in into Hillrom and do a lot of work to reestablish lines of supply into the business. When the semiconductor prices hit, Baxter was better prepared to handle that than Hillrom was. And what we did is we put our best to handle issues primarily Front Line Care.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 25, \"uuid\": \"392a416f-20a8-47da-96a5-750d95c99b89\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 60, "text": "The supply chain really came through for us and today is doing a much better job. As a matter of fact, we have better performance than we planned in Front Line Care in the third quarter because we were able to get that product -- the products out of the door. We also have extremely confident management in our both business. We have Reaz Rasul. Rasul, the head of Front Line Care. We have Andy Frye, the Head of GSS and PSS. So we are very confident in the business we purchased. The business has the ability to perform. We will fix the supply chain issues. That's what we're currently doing, and we'll be able to get back to Hillrom that we made assumptions to buy.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Jose E. Almeida\", \"section_number\": 25, \"uuid\": \"392a416f-20a8-47da-96a5-750d95c99b89\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 61, "text": "As you heard from Jay, our growth would have been ex supply chain, what we had expected to be. So I think Baxter brought to Hillrom a combination of great portfolio. Hillrom brings with great management and discipline that Baxter has to replace the team that was there and we'll say we probably to do in the long term a better job of this combination.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Jose E. Almeida\", \"section_number\": 25, \"uuid\": \"392a416f-20a8-47da-96a5-750d95c99b89\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by Rick Wise", "id": 62, "section": [{"id": 63, "text": "Got you. Maybe I'll change the topic a little bit for my follow-up. You talked about passing along the cost pressures, and you're in the process or you're well long signing new price agreements. Can you help us think through -- I mean, are you -- is this 100% of your business? How do we think about the impact? And just even touchy-feely, Jay, how do we sort of factor that into our thinking as we look ahead to '23 that you could have another 50 basis points of price on half the portfolio? Any extra depth or color perspective would be great. Thank you so much.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Rick Wise\", \"section_number\": 26, \"uuid\": \"8f44d9fb-c01e-4ebc-8eed-c4b65ae64006\", \"speaker_title\": \"Analyst at Stifel\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 64, "section": [{"id": 65, "text": "Rick, you have great questions. So we're going to split, Jay and me here. But let me start by saying that we do not comment in pricing on general course of business. But as Baxter has taken so much into input costs that went up significantly in the last two years, we are very focused in recouping a portion of that, if at all possible. So we already had, as I mentioned, price actions throughout the year. But I would say that beyond what I have said, I'm not going to comment on any specifics about pricing discussions or agreements with our customers.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 27, \"uuid\": \"eab36e38-963b-49db-b418-2538c11c594d\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 66, "text": "But I can say to you, in my opening remarks, as I said, we strongly prefer to build on our long-term relationships with our customers to reach agreements on how best to share an increased cost of delivering products to them, which cost us a significant amount of more money because the cost of oil, the cost of logistics, cost of raw materials, cost of delivery and everything that goes in. We have made significant process -- I'm sorry, I'd rather say, we have made significant progress towards that end. But to the extent that we do not reach agreement with any customer, we will, of course, continue to evaluate the options in front of us to recover the increased cost of our delivering on our mission to serve patients.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Jose E. Almeida\", \"section_number\": 27, \"uuid\": \"eab36e38-963b-49db-b418-2538c11c594d\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 67, "text": "This is very important to us because Baxter -- if you ask any of our 65,000 employees, it's all about the mission of the company. It's an incredible company. I came here seven years ago almost to the date. And I continue to be impressed by the dedication of our employees. But we took a significant amount of cost increase in the last two years. In our input cost and supply chain has done a great job trying to defray that and offset. But as you can see by our margins, it's not possible. We would like that to be a partnership with our suppliers to continue to understand that for us to deliver what we're delivering to them and the innovation in the products, we need that partnership to continue on. So -- and I will end there and pass on to Jay.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Jose E. Almeida\", \"section_number\": 27, \"uuid\": \"eab36e38-963b-49db-b418-2538c11c594d\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by James Saccaro", "id": 68, "section": [{"id": 69, "text": "Sure. Rick, I don't want to get into too much detail on specifics around price and what pieces of the portfolio and so on. But it's safe to say price -- we expect price will be a positive contributor to our numbers next year in 2023. The other thing I would say is we -- it is something that we look at in every single market, in every product line. Why? Because in every one of our areas, we have been challenged with very high levels of inflation, very high levels of incremental costs. So from our perspective, we really have to challenge every sale to make sure that we're garnering enough profit from it and offsetting some of the significant costs that we had.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 28, \"uuid\": \"714e4448-a489-4eb1-acc6-22ca0a48a609\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Rick Wise", "id": 70, "section": [{"id": 71, "text": "Thank you very much.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Rick Wise\", \"section_number\": 29, \"uuid\": \"0f06ce66-690a-42f5-a991-3156125778b9\", \"speaker_title\": \"Analyst at Stifel\"}"}]}, {"title": "Remarks by James Saccaro", "id": 72, "section": [{"id": 73, "text": "Thanks.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 30, \"uuid\": \"a3238df2-c712-466d-8d22-26ad0fdbe268\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Pito Chickering", "id": 74, "section": [{"id": 75, "text": "Good morning guys. Thanks for taking my question. Look you mentioned that you haven't seen any cancellations due to hospital capex pressures and that the backlog remains full here. How do you look at new orders on that backlog versus supply issues sort of keeping the backlog high? And are you seeing any impact to new sales versus historical levels as hospitals struggle with lower margins and lower cash flows?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Pito Chickering\", \"section_number\": 32, \"uuid\": \"5eb5c886-9fdf-47a7-9506-8d20c8b37c31\", \"speaker_title\": \"Analyst at Deutsche Bank\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 76, "section": [{"id": 77, "text": "We have seen sporadic cancellations of orders in institutions that are small and have labor issues in implementing capex projects that sometimes are large. But for the most part, we haven't seen that wave of retraction of capital programs. As a matter of fact, if we could make three times, four times more infusion pumps, we would have sold, I believe, those pumps. If we had made twice as many of the -- our monitors, we would have sold the monitors. So it becomes a little different when it comes to beds. Beds are a larger implementation and software, software like NursePool, a button software like Bolt becomes more elaborate.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 33, \"uuid\": \"191cad00-e898-4572-9f95-4ea84d65cb2e\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 78, "text": "Those are the ones that sometimes receive postponement, not because of the price, but more because of the labor -- not because of the cost, I mean, I should say but more because of the labor. So at the moment in time, I don't believe we're seeing a retraction in the capital market. We're seeing a high cost of labor for hospitals and a shortage of labor that makes difficult for them to undertake large programs sometimes.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Jose E. Almeida\", \"section_number\": 33, \"uuid\": \"191cad00-e898-4572-9f95-4ea84d65cb2e\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by Pito Chickering", "id": 79, "section": [{"id": 80, "text": "Okay. Fair enough. And then a follow-up on the supply chain. Can you break out the $100 million of impact to revenues in 3Q on semiconductors versus the other raw materials? Out of curiosity, what are this other raw material shortages? And then on the semiconductor side, the macro data shows that the pressure peak sort of end of 2Q has been improving sort of during 3Q. So curious if you see any semiconductor shortage improvement from July into versus October.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Pito Chickering\", \"section_number\": 34, \"uuid\": \"11137868-dd14-4628-acdd-8225618d49ad\", \"speaker_title\": \"Analyst at Deutsche Bank\"}"}]}, {"title": "Remarks by James Saccaro", "id": 81, "section": [{"id": 82, "text": "Sure. So a couple of things I would say related to this question. First, the vast majority of the sales impact relates to semiconductors. I would say that over 90% of the challenges that we faced relate to semiconductors. There are other select areas where we have seen a meaningful impact. For example, in our Nutrition business, and there are certain ingredients and vitamins that we're unable to secure due to supplier challenges. And that's had an impact as well, but the majority relates to semiconductors.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 35, \"uuid\": \"aac1287f-5e72-4d2f-861b-38c705d4f491\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}, {"id": 83, "text": "Now as it relates to your semiconductor question, the type of semiconductor used in medical devices is a little bit different than standard semiconductors that are used in the most -- the highest tech products available today. And so while there has certainly been a curtailment of demand for some of these consumer products, the size of the semiconductor that we use does not benefit from this curtailment of demand and normalization of supply. And I would even say for some semiconductor manufacturers, they are seeing inventory levels build of the super thin semiconductor. And so we just have not yet seen this normalize. In our case, we are all-hands-on-deck working to secure the components that we need, and we'll continue to do that. But this is something that, as I said, we don't have a pathway for this getting resolved in the immediate term. Joe, I don't know if you'd like to add anything to that.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"James Saccaro\", \"section_number\": 35, \"uuid\": \"aac1287f-5e72-4d2f-861b-38c705d4f491\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 84, "section": [{"id": 85, "text": "More so, what we're doing is because we're seeing this decision with this the semiconductor manufacturers, not all chips are created the same. So you hear Intel sales are down quite a bit. In PC, this is good news. For our chips, it's not. We don't use the same chips at all. We actually use very little -- very few chips from Intel for instance. We use -- our chips are IoT, Internet of Things. They're thicker. They're much thicker and they are chips that are using better software. So that demand, by the way, some of these chips are about 12% of the semiconductor output -- industry output. So because of that, we work very close now, directly with companies, we're very -- being very successful with the few companies that are working very well with us.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 36, \"uuid\": \"8ec0a966-2cce-4976-bb48-66bf1a1683c2\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 86, "text": "But what we also do, instead of redesign program for our boards, we have identified critical components, we have started a process in our Renal business to redesign 30 of our boards with one of our suppliers. And we have in Front Line Care, a program started right now to replace six key semiconductors that may be constrained in the next 18 months with redesign of boards. So redesign of boards is not as simple as everybody thinks. It's not a plug and play because the form and fit and function of the semiconductors change. We have to redesign the board. We have sometimes to revalidate and clinically revalidate the board. So saying just that we're redesigning boards, the panacea is not. It's all-hands-on-deck.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Jose E. Almeida\", \"section_number\": 36, \"uuid\": \"8ec0a966-2cce-4976-bb48-66bf1a1683c2\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 87, "text": "It's finding new ways to deal with our current suppliers. It's buying directly from them, buying through brokers throughout the world, inventory that is available as well as redesigning the boards so we can have alternates that can be put in, in the future. So it is -- we became a much more sharp company when it comes to semiconductors and boards. And this process is -- despite the fact, it's very painful. We had to acquire significant expertise in this area. It's going to pay dividends in the future.", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Jose E. Almeida\", \"section_number\": 36, \"uuid\": \"8ec0a966-2cce-4976-bb48-66bf1a1683c2\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by Pito Chickering", "id": 88, "section": [{"id": 89, "text": "Okay. Great. And Joe, just a sort of quick follow-up on the first question, just to make sure I have this right. You're saying that new orders for capital equipment in the last 90 days in 2022 is sort of in line or better than it was at this time in 2021 for new orders. Thanks so much.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Pito Chickering\", \"section_number\": 37, \"uuid\": \"c8e2d7bb-8eed-49e8-b875-d0e7dfc10107\", \"speaker_title\": \"Analyst at Deutsche Bank\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 90, "section": [{"id": 91, "text": "No. I'm saying that, in 2021, this time of the year, last year in 2021, we were not -- we did not own Hillrom, but their orders were extremely high. Primarily, the rentals were extremely high because of COVID, okay? What I'm saying to you is we have not seen our book of business be affected by capital constraints. Now and going forward, what we see is delays in some accounts due to labor shortages and primarily large installations, but we have continued dialogue with everyone about our orders.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 38, \"uuid\": \"ef61737a-ee25-48a5-b804-088d11716c61\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}, {"id": 92, "text": "As a matter of fact, I'm planning to see in the first quarter next year, a large installation that we're going to probably be doing in hospitals in the U.S. So I don't see -- we don't see today a significant change in the order pattern in capital. That's what I meant. I'm not comparing to 2021, which had significant high rental revenue into Hillrom because the COVID effect primarily, as you know, coming out of the summer and going into Omicron in October, November of last year.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Jose E. Almeida\", \"section_number\": 38, \"uuid\": \"ef61737a-ee25-48a5-b804-088d11716c61\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by Pito Chickering", "id": 93, "section": [{"id": 94, "text": "Great. Thanks so much guys.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Pito Chickering\", \"section_number\": 39, \"uuid\": \"e7717d8d-11b8-4919-99eb-2ac96ad0ddfe\", \"speaker_title\": \"Analyst at Deutsche Bank\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 95, "section": [{"id": 96, "text": "Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 40, \"uuid\": \"ff6b003b-aa4b-4a3e-9a36-2d797f1a9549\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by Joanne Wuensch", "id": 97, "section": [{"id": 98, "text": "Thank you for taking my question. Briefly, it sounds like you have significant back orders and backlogs. What is happening to those orders? Are they being fulfilled by somebody else? Are they just piling up so that at some stage in the future, they get met? And I'll toss my second question in at the same time. It sounds like you're also working to get better expense synergies out of Hillrom. Is there a way to quantify what you think those may be now versus what you thought they would be before? Thank you.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Joanne Wuensch\", \"section_number\": 42, \"uuid\": \"ed90f3d8-4384-40fb-87b5-3653d2a683bb\", \"speaker_title\": \"Analyst at Citi\"}"}]}, {"title": "Remarks by James Saccaro", "id": 99, "section": [{"id": 100, "text": "Sure. So from a backlog standpoint, overall, we are seeing those orders for the most part, stay in place. We're not seeing others take share as a result of this constrained supply environment that we have in place. And frankly, a number of manufacturers have similar challenges. Now the question is how long will those orders remain. In some cases, if there's short-term needs, then those are things that perhaps might be impacted. But as we think about longer term, for the most part, I think that these sales will represent some level of opportunity in the future. As it relates to Hillrom, we feel very good about where things are trending with the exception of the constraints that we have in place.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 43, \"uuid\": \"b657a01a-6d37-43f8-aef3-1a9a66db64b1\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}, {"id": 101, "text": "And so we highlighted increased incremental cost capture at the May Investor Day, and we're still trending along those lines very much in line with that with increasing confidence. I mean I think it's important because we have some big step-ups as we move to 2023 and 2024 in terms of incremental cost synergies. What's great at this point is, as we sit here today, we feel we have clear line of sight and continue to make progress towards those numbers. So I think as far as that goes, it's a very good story.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"James Saccaro\", \"section_number\": 43, \"uuid\": \"b657a01a-6d37-43f8-aef3-1a9a66db64b1\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Joanne Wuensch", "id": 102, "section": [{"id": 103, "text": "Thanks.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Joanne Wuensch\", \"section_number\": 44, \"uuid\": \"fccb4276-812e-48f9-98bb-76a1582dd3c0\", \"speaker_title\": \"Analyst at Citi\"}"}]}, {"title": "Remarks by James Saccaro", "id": 104, "section": [{"id": 105, "text": "Thank you, Joanne.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 45, \"uuid\": \"8899a786-69d2-4c67-bfec-37853561e171\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Clare Trachtman", "id": 106, "section": [{"id": 107, "text": "We have time for one more question.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Clare Trachtman\", \"section_number\": 46, \"uuid\": \"73663555-fb2c-432f-8cdd-0ef9e9f09fe3\", \"speaker_title\": \"Vice President of Investor Relations at Baxter International\"}"}]}, {"title": "Remarks by Joshua Jennings", "id": 108, "section": [{"id": 109, "text": "Hi. Good morning. Thanks so much. Joe, maybe I wanted to ask just about connected care initiatives and just how -- anything you can share with us on progress post the Hillrom acquisition on developing these connected care technologies or programs? And how should we be thinking about updates and tracking the progress? And then maybe just a second question for Jay, just thinking about the target of getting down to 2.75 times net leverage in 2024. Can you just help us think through some of the puts and takes and your confidence level in terms of -- that you are on pace to hit that target? Thanks for taking the questions.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Joshua Jennings\", \"section_number\": 48, \"uuid\": \"6b752430-5d9d-4eac-8de5-b1226ac3b9e7\", \"speaker_title\": \"Analyst at Cowen\"}"}]}, {"title": "Remarks by Jose E. Almeida", "id": 110, "section": [{"id": 111, "text": "Josh, good morning. So we are seeing several programs where we are working across divisions in the connected care. We established a new group that is actually under Andy Frye, one of our executives who is also the Head of GSS and PSS, Patient Support System. And we are seeing several programs from basic creating unified portals to access EMR systems in hospitals to features that can be enabled by commonality and connecting the devices. So there's a lot going on. I think we should give an update to investors, probably in the first quarter of 2023, about where we are with these connected care programs. And so we have a brand-new group that is now across Baxter, that is looking at this and creating opportunities. So we're making good progress in this area. I'll pass on to Jay for answering the other question.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Jose E. Almeida\", \"section_number\": 49, \"uuid\": \"1aeaab45-4102-48cb-ad5f-bf1a56d3f5b0\", \"speaker_title\": \"Chairman of the Board, President & Chief Executive Officer at Baxter International\"}"}]}, {"title": "Remarks by James Saccaro", "id": 112, "section": [{"id": 113, "text": "Sure. As you know, we're really focused on maintaining solid investment-grade credit ratings. We define that as BBB. So the rating that we currently have is one that we're targeting maintaining. And in order to do that, we want to make very good progress towards the 2.75 net debt-to-EBITDA, which is our objective. I would say that from a cash flow standpoint, this year has fallen short of our expectations. And I would say that, of course, we've had some challenges on the income statement. But as we look at inventory, we had a fairly substantial inventory build over the course of the year, which is interesting because what's happening is you have a pump which is lacking one critical component, and so you're unable to sell that pump until you get that critical component, for example. We also saw extended shipping lane times over the course of the year and increases in the cost of our inventory due to our suppliers. And so for all those reasons, we've had a very challenging year from an inventory standpoint.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"James Saccaro\", \"section_number\": 50, \"uuid\": \"5df36e53-0f7b-4a29-8ebe-45bbd76aa6b2\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}, {"id": 114, "text": "I would note that in the first -- in the third quarter, we did see a decline in inventory, and we are expecting a fairly substantial improvement in free cash flow in the fourth quarter, as is typically the case. But here's the interesting thing. While net income growth next year is low, free cash flow growth, we expect to be substantial. And so we're still finalizing our plans, but you're going to start to see a very significant acceleration of free cash flow growth as the inventory situation normalizes over the next one to two years. And that will really support some of the work that we're doing to get to 2.75 times net debt-to-EBITDA, which again, is a clear focus for our entire management team.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"James Saccaro\", \"section_number\": 50, \"uuid\": \"5df36e53-0f7b-4a29-8ebe-45bbd76aa6b2\", \"speaker_title\": \"Executive Vice President & Chief Financial Officer. at Baxter International\"}"}]}, {"title": "Remarks by Joshua Jennings", "id": 115, "section": [{"id": 116, "text": "Thanks so much.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Joshua Jennings\", \"section_number\": 51, \"uuid\": \"ed12ee32-8817-4140-9f7f-07772f6f86a6\", \"speaker_title\": \"Analyst at Cowen\"}"}]}, {"title": "Remarks by Clare Trachtman", "id": 117, "section": [{"id": 118, "text": "Thank you very much.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Clare Trachtman\", \"section_number\": 52, \"uuid\": \"7f4c5bb8-0330-4ff7-a9b2-b983c6372c9b\", \"speaker_title\": \"Vice President of Investor Relations at Baxter International\"}"}]}], "title": "Q&A for BAX (Baxter International) on 10/27/22 8:30 AM ET", "metadata_json": "{\"company_name\": \"Baxter International\", \"company_ticker\": \"BAX\", \"transcript_date\": \"10/27/22 8:30 AM ET\", \"section_type\": \"Q&A\", \"transcript_url\": \"https://www.marketbeat.com/earnings/transcripts/80155/\"}"}